Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
1,392
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings

Sabina Chiarettia Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyCorrespondence[email protected]
View further author information
,
Akram Taherinasaba Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Irene Della Starzaa Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, Italy;b Fondazione GIMEMA Onlus, Rome, ItalyView further author information
,
Martina Canichellaa Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Michela Ansuinellia Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Maria Stefania De Proprisa Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Monica Messinab Fondazione GIMEMA Onlus, Rome, ItalyView further author information
,
Orietta Spinellic Haematology and Bone Marrow Transplant Unit, ASST-Papa Giovanni XXIII, BergamoView further author information
,
Alessandra Santorod Department of Hemato Oncology, AOR “VillaSofia-Cervello”, Palermo, ItalyView further author information
,
Lucia Anna De Novia Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Deborah Cardinalia Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
,
Mattia Schipanie Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale and Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, ItalyView further author information
,
Valentina Arenab Fondazione GIMEMA Onlus, Rome, ItalyORCID Iconhttps://orcid.org/0000-0003-2782-2752View further author information
ORCID Icon,
Renato Bassanf Division of Hematology, Ospedale dell’Angelo, Mestre, Venezia, ItalyORCID Iconhttps://orcid.org/0000-0001-8214-2894View further author information
ORCID Icon,
Anna Guarinig Department of Molecular Medicine, “Sapienza” University of Rome, ItalyView further author information
&
Robin Foàa Hematology, Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, ItalyView further author information
 show all
Pages 483-486 | Received 31 Aug 2022, Accepted 27 Oct 2022, Published online: 19 Dec 2022

References

  • Jf LI, Dai YT, Lilljebjörn H, et al. Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci USA. 2018;115: e11711–11720.
  • Zaliova M, Stuchly J, Winkowska L, et al. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive european cohort. Haematologica. 2019;104(7):1396–1406.
  • Paietta E, Roberts KG, Wang V, et al. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021;138(11):948–958.
  • Moorman AV, Barretta E, Butler ER, et al. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 2022;36(3):625–636.
  • Chiaretti S, Messina M, Della Starza I, et al. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica. 2021;106(6):1559–1568.
  • Gu Z, Churchman ML, Roberts KG, et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019;51(2):296–307.
  • Yamamoto H, Hayakawa F, Yasuda T, et al. ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities. FEBS Lett. 2019;593(16):2151–2161.
  • Qian M, Zhang H, Kham SK, et al. Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP. Genome Res. 2017;27(2):185–195.
  • Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–379.
  • Hirabayashi S, Ohki K, Nakabayashi K, et al. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype. Haematologica. 2017;102(1):118–129.
  • Hirabayashi S, Butler ER, Ohki K, et al. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the ponte di legno childhood ALL working group. Leukemia. 2021;35(11):3272–3277.
  • Liu YF, Wang BY, Zhang WN, et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine. 2016;8:173–183.
  • Qin YZ, Jiang Q, Xu LP, et al. The prognostic significance of ZNF384 fusions in adult Ph-Negative B-Cell precursor acute lymphoblastic leukemia: a comprehensive cohort study from a single chinese center. Front Oncol. 2021;11:632532.
  • Bassan R, Chiaretti S, Della Starza INational pegaspargase-modified risk-oriented program for Philadelphia-negative adult acute lymphoblastic leukemia/lymphoblastic lymphoma (Ph − ALL/LL). GIMEMA LAL 1913 final results. EHA meeting, 9-17 June, et al. 2022. S113.
  • Bassan R, Chiaretti S, Della Starza I, et al. Preliminary results of the GIMEMA LAL2317 sequential chemotherapy-blinatumomab front-line trial for newly diagnosed adult Ph-negative B-lineage ALL patients. EHA meeting, 9–17, June. 2021, S114.
  • Jeha S, Choi J, Roberts KG, et al. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy. Blood Cancer Discov. 2021;2(4):326–337.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.